Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session on Gynaecological tumours

242MO - Sarcopenia as A Predictor of Overall Survival in Patients with Ovarian Cancer Undergoing Chemotherapy : A Systematic Review and Meta-Analysis


22 Nov 2020


Mini oral session on Gynaecological tumours


Vika Damay


V. Damay1, F. Kwenandar1, K.V. Japar1, T.I. Hariyanto1, P. Wibisono2, A. Kurniawan3

Author affiliations

  • 1 Medicine, UPH - Pelita Harapan University - Faculty of Medicine, 15810 - Tangerang/ID
  • 2 Medicine, University of Pelita Harapan, 15811 - Tangerang/ID
  • 3 Department Of Internal Medicine, Faculty of Medicine, Pelita Harapan University, 15811 - Tangerang/ID


Login to access the resources on OncologyPRO.

Abstract 242MO


Loss of skeletal muscle or sarcopenia is commonly seen in various types of malignancy, including ovarian cancer. While some studies suggest sarcopenia as prognostic factor associated with poor survival during chemotherapy, other studies shown no significant association between the two. This meta-analysis aims to investigate whether or not sarcopenia significantly associated with poor survival in ovarian cancer patients undergoing chemotherapy.


A systematic review was conducted using PRISMA guideline. Online databases (PubMed, PubMed Central and Google Scholar) were searched for relevant terms related to sarcopenia in ovarian cancer patients undergoing chemotherapy with overall survival as our outcome in this study. We used Newcastle Ottawa Scale to assess the quality of our studies. Meta-analysis was later performed using Review Software Manager.


A total of 4 studies are eligible and therefore included in the analysis. All studies were observational studies consisting 653 patients with ovarian cancer. Our included studies each shows “good” quality according to Newcastle Ottawa Scale. Our meta-analysis showed no significant association between sarcopenia and overall survival in ovarian cancer patients receiving chemotherapy (HR 1.54; 95% CI 0.98-2.42; P = 0.06).


Our study result shows that sarcopenia did not influence overall survival of ovarian cancer patients receiving chemotherapy. Future studies should involve more number of patients.

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings